Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anti-PD1/PDL1 Antibody”

83 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 83 results

Testing effectiveness (Phase 2)Study completedNCT04732494
What this trial is testing

Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma
BeiGene 125
Testing effectiveness (Phase 2)Study completedNCT02129556
What this trial is testing

Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer

Who this might be right for
Metastatic Breast Cancer
ETOP IBCSG Partners Foundation 58
Early research (Phase 1)Looking for participantsNCT07027514
What this trial is testing

Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Ankyra Therapeutics, Inc 60
Testing effectiveness (Phase 2)Looking for participantsNCT06827236
What this trial is testing

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Who this might be right for
Locally Advanced Breast CancerUnresectable Breast CarcinomaMetastatic Breast Cancer
BioNTech SE 380
Testing effectiveness (Phase 2)Looking for participantsNCT07130032
What this trial is testing

Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade

Who this might be right for
Metastatic Non-small Cell Lung Cancer (NSCLC)Metastatic Cutaneous Melanoma
EuroCityClinic LLC 90
Testing effectiveness (Phase 2)Study completedNCT05215067
What this trial is testing

A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non-small Cell Lung Cancer
Akeso 44
Large-scale testing (Phase 3)Active Not RecruitingNCT05785767
What this trial is testing

Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Regeneron Pharmaceuticals 850
Testing effectiveness (Phase 2)Looking for participantsNCT06941857
What this trial is testing

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 20
Large-scale testing (Phase 3)Not Yet RecruitingNCT07361484
What this trial is testing

Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)

Who this might be right for
Non-Small Cell Lung CancerNon-squamous Non-Small Cell Lung Cance
BeyondSpring Pharmaceuticals Inc. 442
Large-scale testing (Phase 3)Active Not RecruitingNCT05800015
What this trial is testing

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Regeneron Pharmaceuticals 950
Large-scale testing (Phase 3)Study completedNCT02504372
What this trial is testing

Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 1,177
Large-scale testing (Phase 3)Looking for participantsNCT06926868
What this trial is testing

Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Who this might be right for
Breast Neoplasms
Bristol-Myers Squibb 500
Large-scale testing (Phase 3)Study completedNCT03134872
What this trial is testing

SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+6 more
Jiangsu HengRui Medicine Co., Ltd. 419
Testing effectiveness (Phase 2)Study completedNCT03861793
What this trial is testing

A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

Who this might be right for
Advanced Solid Tumors
Mural Oncology, Inc 116
Testing effectiveness (Phase 2)Active Not RecruitingNCT05604560
What this trial is testing

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Who this might be right for
Pancreatic Cancer
Lei Zheng 25
Early research (Phase 1)Looking for participantsNCT06022029
What this trial is testing

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

Who this might be right for
Triple Negative Breast CancerDiffuse Large B Cell LymphomaFollicular Lymphoma+11 more
OncoNano Medicine, Inc. 168
Testing effectiveness (Phase 2)Active Not RecruitingNCT04931654
What this trial is testing

Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

Who this might be right for
Carcinoma, Non-Small-Cell LungGastric CancerGastroesophageal Junction Cancer
AstraZeneca 136
Testing effectiveness (Phase 2)Study completedNCT02694822
What this trial is testing

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

Who this might be right for
Advanced Solid CancersAdvanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies
Agenus Inc. 89
Large-scale testing (Phase 3)Ended earlyNCT03515629
What this trial is testing

REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Regeneron Pharmaceuticals 5
Large-scale testing (Phase 3)Looking for participantsNCT07044336
What this trial is testing

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Who this might be right for
Endometrial CancerMalignant Solid Tumour
AstraZeneca 800
Load More Results